文献速递白血病

急性淋巴细胞白血病的维持治疗:基础科学与临床转化

Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
PubMed 文献 · Leukemia · 2022-06-02

口服甲氨蝶呤(MTX)与6-巯基嘌呤(6-MP)维持治疗(MT)是治愈急性淋巴细胞白血病(ALL)的关键。MTX与6-MP干扰核苷酸合成与补救途径,主要细胞毒机制涉及硫鸟嘌呤核苷酸(TGNs)掺入DNA(DNA-TG)。多种遗传多态性影响药物代谢、疗效与毒性,DNA-TG水平较高与较低复发风险相关,据此开发了硫嘌呤增强ALL维持(TEAM)策略,正在随机ALLTogether1试验中测试。

要点

  • MTX与6-MP维持治疗是ALL治愈的关键环节。
  • DNA-TG水平较高与较低复发风险相关。
  • TEAM策略(低剂量6-硫鸟嘌呤加入6-MP/MTX骨架)正在随机试验中测试。

核心结论

  • DNA-TG是MTX/6-MP联合化疗的共同下游代谢物,较高DNA-TG水平与较低复发风险相关,据此开发了TEAM策略并正在随机ALLTogether1试验中测试。

研究设计与样本

  • 综述,总结维持治疗的基础科学与临床转化研究。

主要发现

  • MTX和6-MP干扰核苷酸合成和补救途径。
  • 主要细胞毒机制涉及硫鸟嘌呤核苷酸(TGNs)掺入DNA(作为DNA-TG),其他MTX/6-MP代谢物抑制从头嘌呤合成可能增强此过程。
  • 维持治疗期间合并用药常见;耶氏肺孢子菌预防似乎安全,但糖皮质激素/长春新碱脉冲改善生存的获益及别嘌呤醇调节6-MP药代动力学的获益仍不确定。
  • 多种遗传多态性影响MTX和硫嘌呤的药理学、疗效和毒性(主要为骨髓抑制和肝毒性)。
  • 硫嘌呤S-甲基转移酶(由TPMT编码)降低TGNs但增加甲基化6-MP代谢物(MeMPs);类似地,nudix水解酶15(由NUDT15编码)也降低可用于DNA掺入的TGNs。

关键数值与推荐

  • TEAM策略为在6-MP/MTX骨架上加用低剂量(2.5-12.5 mg/m2/天)6-硫鸟嘌呤,目前正在随机ALLTogether1试验(EudraCT: 2018-001795-38)中测试。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 糖皮质激素/长春新碱脉冲改善生存的获益及别嘌呤醇调节6-MP药代动力学的获益仍不确定。
  • TPMT和NUDT15功能缺失变异不能完全解释硫嘌呤毒性的患者间变异。
  • 传统上由骨髓抑制程度指导的剂量调整不能准确反映治疗强度。
  • TEAM策略目前正在随机ALLTogether1试验中测试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with nucleotide synthesis and salvage pathways. The primary cytotoxic mechanism involves the incorporation of thioguanine nucleotides (TGNs) into DNA (as DNA-TG), which may be enhanced by the inhibition of de novo purine synthesis by other MTX/6-MP metabolites. Co-medication during MT is common. Although Pneumocystis jirovecii prophylaxis appears safe, the benefit of glucocorticosteroid/vincristine pulses in improving survival and of allopurinol to moderate 6-MP pharmacokinetics remains uncertain. Numerous genetic polymorphisms influence the pharmacology, efficacy, and toxicity (mainly myelosuppression and hepatotoxicity) of MTX and thiopurines. Thiopurine S-methyltransferase (encoded by TPMT) decreases TGNs but increases methylated 6-MP metabolites (MeMPs); similarly, nudix hydrolase 15 (encoded by NUDT15) also decreases TGNs available for DNA incorporation. Loss-of-function variants in both genes are currently used to guide MT, but do not fully explain the inter-patient variability in thiopurine toxicity. Because of the large inter-individual variations in MTX/6-MP bioavailability and metabolism, dose adjustments are traditionally guided by the degree of myelosuppression, but this does not accurately reflect treatment intensity. DNA-TG is a common downstream metabolite of MTX/6-MP combination chemotherapy, and a higher level of DNA-TG has been associated with a lower relapse hazard, leading to the development of the Thiopurine Enhanced ALL Maintenance (TEAM) strategy-the addition of low-dose (2.5-12.5 mg/m2/day) 6-thioguanine to the 6-MP/MTX backbone-that is currently being tested in a randomized ALLTogether1 trial (EudraCT: 2018-001795-38). Mutations in the thiopurine and MTX metabolism pathways, and in the mismatch repair genes have been identified in early ALL relapses, providing valuable insights to assist the development of strategies to detect imminent relapse, to facilitate relapse salvage therapy, and even to bring about changes in frontline ALL therapy to mitigate this relapse risk.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Toksvang LN, Lee SHR, Yang JJ, et al. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. 2022. PMID: 35654820. doi:10.1038/s41375-022-01591-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。